Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $43.20.

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 15,485 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70. Following the completion of the sale, the insider now owns 74,158 shares of the company’s stock, valued at $2,419,033.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Andrew Cheng sold 108,366 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $19,209,881.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Catriona Yale sold 15,485 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70. Following the sale, the insider now directly owns 74,158 shares of the company’s stock, valued at approximately $2,419,033.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 428,397 shares of company stock valued at $12,997,971 over the last 90 days. 7.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its holdings in shares of Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after buying an additional 1,183 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares during the period. Eastern Bank bought a new stake in Akero Therapeutics during the 3rd quarter valued at about $100,000. Headlands Technologies LLC boosted its position in Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after buying an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after purchasing an additional 1,030 shares during the period.

Akero Therapeutics Stock Down 2.0 %

Akero Therapeutics stock opened at $32.38 on Wednesday. Akero Therapeutics has a twelve month low of $13.47 and a twelve month high of $37.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The firm has a market cap of $2.25 billion, a PE ratio of -8.81 and a beta of -0.26. The firm’s 50 day moving average price is $29.14 and its two-hundred day moving average price is $25.37.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts predict that Akero Therapeutics will post -3.64 EPS for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.